IgA Nephropathy, Lymphocyte Homing and IgA Class Switch (NIDOCIGA)

University of Limoges (UL)

Status: Completed

Conditions: IgA Nephropathy

Treatments: Other: blood test

Study type: Interventional

Funder types: Other

Identifiers

NCT01775527

I10 014

Details and patient eligibility

About

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure. This disease was described as a distinct entity in 1968 by J Berger and N Hinglais. The aetiology and the pathogenesis remain still obscure. Clinical observations and immunisation studies indicate that IgAN represents a dysregulation of the immune system, rather than an intrinsic renal abnormality. Twenty years ago, some authors proposed the mucosa-bone marrow axis to explain the pathogenesis of the disease. Mucosal IgA plasmocytes are displaced and take up residence in systemic sites. The unusual characteristics featured by the IgA produced by these cells (charge, size, glycosylation) drive their accumulation, deposition and mesangial activation characteristic of IgAN.

Evidence is emerging that altered lymphocyte homing may ultimately explain this aberrant localization.

Enrollment: 72 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age > 18 and < 70 years
• IgA nephropathy documented by the kidney biopsy in the six months preceding the inclusion
• Glomerular filtration rate (MDRD formula as simplified) < 90 ml/mn and > 30 ml/mn/1,73 m2
• Consent form signed

Exclusion criteria

• Patients with cirrhosis or chronic liver disease
• Patients with a history of Crohn's disease or celiac disease
• Patients who received treatment with corticosteroids or affiliates for six months
• Patients who received a live attenuated vaccine during the past 4 weeks
• Patients with a known infection such as HIV, hepatitis B or C
• Patients who presented with a serious infection during the last month
• Breastfeeding women
• Patients not affiliated with a social security scheme
• Under guardianship patient

Trial design

72 participants in 1 patient group

blood test

Other group

Treatment:

Other: blood test